Oxford Biomedica (OXBDF) News Today → What is the 72-Hour Profit Surge? (From DTI) (Ad) Free OXBDF Stock Alerts $2.72 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineOxford BioMedica PLCbarrons.com - April 20 at 3:44 PMOxford Biomedica Insiders Placed Bullish Bets Worth UK£415.3kfinance.yahoo.com - March 30 at 10:23 AMOxford BioMedica PLC (OXB)investing.com - January 23 at 11:53 PMOxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturingfinance.yahoo.com - January 23 at 8:52 AMOxford BioMedica PLC OXOAmorningstar.com - November 5 at 12:41 AMAnalysts Just Slashed Their Oxford Biomedica plc (LON:OXB) EPS Numbersfinance.yahoo.com - September 25 at 4:56 AMOxford Biomedica (OTCMKTS:OXBDF) Price Target Cut to GBX 325 by Analysts at JPMorgan Chase & Co.marketbeat.com - September 22 at 4:52 PMOxford BioMedica shares boom as manufacturer expands complex cancer therapiesmsn.com - September 21 at 1:16 PMOxford BioMedica shares up, in talks to buy ABL Europe but loss widenslse.co.uk - September 20 at 8:20 AMOxford Biomedica stock soars on rosy forecast, talks to buy ABL Europemsn.com - September 20 at 8:20 AMOxford BioMedica Shares Rise on Transformational Deal Talks, Revenue Growth Expectationmarketwatch.com - September 20 at 8:20 AMOxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformationfinance.yahoo.com - September 20 at 8:20 AMKyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platformfinance.yahoo.com - September 20 at 8:20 AMOxford Biomedica to host webinar showcasing the TetraVecta™ systemfinance.yahoo.com - September 7 at 8:04 AMOxford Biomedica (LON:OXB) shareholders have endured a 50% loss from investing in the stock five years agofinance.yahoo.com - July 10 at 6:00 AMOxford BioMedica's Executive Pay Report Gets Low Shareholder Support at Annual Meetingmarketwatch.com - June 23 at 2:59 PMDr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023finance.yahoo.com - February 20 at 9:12 AMThe past year for Oxford Biomedica (LON:OXB) investors has not been profitablefinance.yahoo.com - January 30 at 8:21 AMOxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 millionfinance.yahoo.com - November 14 at 8:33 AMOxford BioMedica swings to interim loss as costs climb, revenue fallslse.co.uk - September 15 at 4:05 PMOxford Biomedica (LON:OXB) shareholders have endured a 66% loss from investing in the stock a year agofinance.yahoo.com - August 19 at 4:22 AMOxford BioMedica begins new project and signs license agreementlse.co.uk - July 26 at 8:43 AMOxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapyfinance.yahoo.com - July 26 at 8:43 AMOxford Biomedica plc's (LON:OXB) Intrinsic Value Is Potentially 20% Below Its Share Pricefinance.yahoo.com - July 16 at 9:55 AMSMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deallse.co.uk - July 1 at 7:41 AMAstraZeneca signs new three-year deal with Oxford Biomedica for COVID shotseekingalpha.com - July 1 at 7:41 AMOxford BioMedica extends Covid vaccine deal with AstraZenecafinance.yahoo.com - July 1 at 7:41 AMUS FDA lifts clinical hold on Oxford BioMedica partner's triallse.co.uk - June 14 at 7:53 AMCould The Market Be Wrong About Oxford Biomedica plc (LON:OXB) Given Its Attractive Financial Prospects?finance.yahoo.com - May 15 at 8:43 AMOxford Biomedica reports 63% revenue growth linked to AstraZeneca vaccine supply: Prelimseekingalpha.com - April 20 at 12:43 PMOxford BioMedica shares fall as warns on 2022 amid Covid jab pauselse.co.uk - April 20 at 7:36 AMOxford BioMedica Sees Lower 2022 Revenue on Suspension of Covid-19 Vaccine With AstraZenecamarketwatch.com - April 20 at 7:36 AMOxford BioMedica warns revenue will be hit by AstraZeneca jab uncertaintyft.com - April 20 at 7:36 AMOxford Biomedica warns on sales after pausing AstraZeneca COVID vaccineuk.finance.yahoo.com - April 20 at 7:36 AMOxford Biomedica Preliminary Resultsfinance.yahoo.com - April 20 at 7:36 AMOxford Biomedica completes deal with Homology Medicines to set up 1st US subsidiaryseekingalpha.com - March 13 at 8:37 AMHomology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedicafinance.yahoo.com - March 10 at 6:23 PMUPDATE: Oxford BioMedica raises GBP80 million via placinglse.co.uk - January 28 at 6:36 PMCORRECT: Oxford BioMedica to acquire 80% ownership of new US businesslse.co.uk - January 28 at 1:36 PMOxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offeringsmarkets.businessinsider.com - January 28 at 1:36 PMOxford BioMedica to acquire 80% ownership of new US virus businesslse.co.uk - January 28 at 8:36 AMOxford BioMedica to Raise GBP80 Mln to Fund US Joint Venturemarketwatch.com - January 28 at 3:35 AMOxford Biomedica in pact with Virica Biotech to improve production of gene therapiesseekingalpha.com - January 24 at 12:41 PMOxford BioMedica CEO to Step Downmarketwatch.com - January 17 at 8:00 AMOxford BioMedica Signs Deal to License, Supply LentiVector Platformmarketwatch.com - January 5 at 7:13 AMWhat Type Of Shareholders Own The Most Number of Oxford Biomedica plc (LON:OXB) Shares?finance.yahoo.com - December 31 at 8:57 AMOxford Biomedica in license and supply deals with Novartis and Arcellxlse.co.uk - December 13 at 9:12 AMOxford BioMedica Extends Agreement With Novartis; Signs Deal With Arcellxmarketwatch.com - December 13 at 4:12 AMOxford Biomedica Signs LSA With Arcellx, Extends Deal With Novartis - Quick Facts markets.businessinsider.com - December 13 at 3:23 AMOxford BioMedica licences technology for cystic fibrosis treatmentlse.co.uk - October 19 at 8:45 AM Get Oxford Biomedica News Delivered to You Automatically Sign up to receive the latest news and ratings for OXBDF and its competitors with MarketBeat's FREE daily newsletter. Email Address $25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time… Go here to watch the most recent trading workshop video at no charge. OXBDF Media Mentions By Week OXBDF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OXBDF News Sentiment▼0.000.41▲Average Medical News Sentiment OXBDF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OXBDF Articles This Week▼20▲OXBDF Articles Average Week Get Oxford Biomedica News Delivered to You Automatically Sign up to receive the latest news and ratings for OXBDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADOCY News ANGO News FENC News XERS News XBIT News CDXC News CHRS News PBYI News BDTX News NKTR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:OXBDF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
